[HTML][HTML] Carbon footprints and life cycle assessments of inhalers: a review of published evidence
B Fulford, K Mezzi, S Aumônier, M Finkbeiner - Sustainability, 2022 - mdpi.com
Respiratory inhalers have a substantial impact on the carbon footprint of the healthcare
sector. Environmental factors, including carbon footprints, are gaining importance in …
sector. Environmental factors, including carbon footprints, are gaining importance in …
[HTML][HTML] Gender differences among Swedish COPD patients: results from the ARCTIC, a real-world retrospective cohort study
K Lisspers, K Larsson, C Janson, B Ställberg… - npj Primary Care …, 2019 - nature.com
The present study aimed to generate real-world evidence regarding gender differences
among chronic obstructive pulmonary disease (COPD) patients, especially as regards the …
among chronic obstructive pulmonary disease (COPD) patients, especially as regards the …
The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD
Background Endpoints that evaluate deterioration rather than improvement of disease may
have clinical utility in COPD. In this analysis, we compared the effects of different …
have clinical utility in COPD. In this analysis, we compared the effects of different …
[HTML][HTML] Indacaterol/glycopyrronium versus salmeterol/fluticasone in the prevention of clinically important deterioration in COPD: results from the FLAME study
AR Anzueto, K Kostikas, K Mezzi, S Shen, M Larbig… - Respiratory …, 2018 - Springer
Background Chronic obstructive pulmonary disease (COPD) is a progressive disease and a
composite endpoint could be an indicator of treatment effect on disease worsening. This …
composite endpoint could be an indicator of treatment effect on disease worsening. This …
Osteoporosis and fracture risk associated with inhaled corticosteroid use among Swedish COPD patients: the ARCTIC study
C Janson, K Lisspers, B Ställberg… - European …, 2021 - Eur Respiratory Soc
The effect of inhaled corticosteroids (ICS) on the risk of osteoporosis and fracture in patients
with chronic obstructive pulmonary disease (COPD) remains uncertain. The aim of this study …
with chronic obstructive pulmonary disease (COPD) remains uncertain. The aim of this study …
Response to Indacaterol/Glycopyrronium (IND/GLY) by sex in patients with COPD: a pooled analysis from the IGNITE program
I Tsiligianni, K Mezzi, S Fucile, K Kostikas… - COPD: Journal of …, 2017 - Taylor & Francis
In this pooled analysis, we compared the effect of indacaterol/glycopyrronium (IND/GLY) by
sex versus other commonly used chronic obstructive pulmonary disease (COPD) treatments …
sex versus other commonly used chronic obstructive pulmonary disease (COPD) treatments …
[HTML][HTML] Cost-effectiveness of the LABA/LAMA dual bronchodilator indacaterol/glycopyrronium in a Swedish healthcare setting
D Price, D Keininger, M Costa-Scharplatz, K Mezzi… - Respiratory …, 2014 - Elsevier
Summary Background Indacaterol/glycopyrronium (IND/GLY) is a once-daily inhaled fixed-
dose combination of indacaterol (IND), a long-acting β 2-adrenergic agonist (LABA), and …
dose combination of indacaterol (IND), a long-acting β 2-adrenergic agonist (LABA), and …
[HTML][HTML] Life-Cycle Assessment of the Breezhaler® Breath-Actuated Dry Powder Inhaler
B Fulford, K Mezzi, A Whiting, S Aumônier - Sustainability, 2021 - mdpi.com
The Breezhaler® dry powder inhaler (DPI) has a low carbon footprint compared with other
inhalation therapies, consistent with the literature on other DPIs. This life-cycle assessment …
inhalation therapies, consistent with the literature on other DPIs. This life-cycle assessment …
The impact of exacerbation frequency on clinical and economic outcomes in Swedish COPD patients: the ARCTIC study
K Larsson, C Janson, K Lisspers… - … Journal of Chronic …, 2021 - Taylor & Francis
Purpose The aim of this study was to assess the association between exacerbation
frequency and clinical and economic outcomes in patients with COPD. Patients and …
frequency and clinical and economic outcomes in patients with COPD. Patients and …
[HTML][HTML] Treatment response to indacaterol/glycopyrronium versus salmeterol/fluticasone in exacerbating COPD patients by gender: a post-hoc analysis in the FLAME …
Background The burden of chronic obstructive lung disease (COPD) is increasing in women,
with recent evidence suggesting gender differences in disease characteristics and …
with recent evidence suggesting gender differences in disease characteristics and …